Lintunen, Jonne http://orcid.org/0000-0001-5627-2388
Lähteenvuo, Markku
Tiihonen, Jari
Tanskanen, Antti
Taipale, Heidi http://orcid.org/0000-0002-3281-934X
Funding for this research was provided by:
Academy of Finland (315969, 320107, 315969, 320107)
Finnish Ministry of Social Affairs and Health: developmental fund for Niuvanniemi Hospital
Article History
Received: 23 September 2020
Accepted: 24 November 2020
First Online: 21 January 2021
Competing interests
: J.L. declares no conflicts of interest. J.T., H.T., and A.T. have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. H.T. reports personal fees from Janssen-Cilag. J.T. reports personal fees from Eli Lilly, Janssen-Cilag, Lundbeck, and Otsuka; and is a member of advisory board for Lundbeck. M.L. is a board member of Genomi Solutions ltd. and DNE ltd., has reports personal fees from Sunovion ltd., Janssen-Cilag and Orion Pharma ltd., and research funding from The Finnish Medical Foundation and Emil Aaltonen Foundation.